Oramed (ORMP) to Conduct Sub-Study on Oral Insulin per FDA Request
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Horizon Pharma (HZNP) Files Generic PENNSAID-Related Patent Suit
- Pfizer (PFE) XELJANZ in RA NDA Accepted for Review by U.S. FDA
- LinnCo (LNCO) Finalizes Agreement with Quantum Energy Partners
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!